 | This articleneeds additional citations forverification. Please helpimprove this article byadding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Brinzolamide" – news ·newspapers ·books ·scholar ·JSTOR(October 2017) (Learn how and when to remove this message) |
 | |
| Clinical data | |
|---|---|
| Pronunciation | brin ZOH la mide |
| Trade names | Azopt |
| Other names | (5R)-5-ethylamino-3-(3-methoxypropyl)-2,2-dioxo-2λ6,9-dithia-3-azabicyclo[4.3.0]nona-7,10-diene-8-sulfonamide |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601233 |
| License data | |
| Pregnancy category | |
| Routes of administration | Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Absorbed systemically, but below detectable levels (less than 10 ng/mL) |
| Protein binding | ~60% |
| Eliminationhalf-life | 111 days |
| Excretion | Kidney (60%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.149.376 |
| Chemical and physical data | |
| Formula | C12H21N3O5S3 |
| Molar mass | 383.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Brinzolamide (trade nameAzopt) is acarbonic anhydrase inhibitor used to lower intraocular pressure in patients with open-angleglaucoma or ocular hypertension.
Brinzolamide was approved as ageneric medication in the United States in November 2020.[2]
Brinzolamide is acarbonic anhydrase inhibitor (specifically, carbonic anhydrase II). Carbonic anhydrase is found primarily inerythrocytes (but also in other tissues including the eye). It exists as a number of isoenzymes, the most active of which is carbonic anhydrase II (CA-II).
Use for the treatment of open-angle glaucoma and raised intraocular pressure due to either excess aqueous humor production or inadequate drainage of the humor via thetrabecular meshwork.
Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion and thus lowers the intraocular pressure in the anterior chamber, presumably by reducing the rate of formation of bicarbonate ions with subsequent reduction in sodium and fluid transport; this may alleviate the effects of open-angle glaucoma.
The recommended frequency for topical application is two times per day. Following ocular instillation, the suspension is systemically absorbed to some degree; however the plasma concentrations are low and generally below the limits of detection (less than 10 ng/mL) due to extensive binding by tissues and erythrocytes. Oral administration is less-favored due to variable absorption from the stomach mucosa and an increased side-effect profile versus ophthalmic administration.
The compound is fairly well protein-bound (60%), but adheres extensively to the carbonic anhydrase-containing erythrocytes. Due to the abundance of readily-bound erythrocytes and minimal known metabolism, Brinzolamide's whole blood half-life is very long (111 days).
While definitive sites of metabolism have not been firmly established, there are several metabolites worthy of note. N-Desethylbrinzolamide is an active metabolite of the parent compound, and thus exhibits carbonic anhydrase inhibitory activity (largely carbonic anhydrase-I, when in the presence of Brinzolamide) and also accumulates in the erythrocytes. However, Brinzolamide's other known metabolites (N-Desmethoxypropylbrinzolamide and O-Desmethylbrinzolamide) either have no activity or their activity is currently unknown.
Brinzolamide is excreted primarily unchanged (60%) in the urine, although the renal clearance rate has not been definitively determined. N-Desethylbrinzolamide is also found in the urine along with lower concentrations of the inactive metabolites, N-Desmethoxypropylbrinzolamide and O-Desmethylbrinzolamide; exact levels have not been definitively determined.
The combination of brinzolamide withtimolol is marketed under the trade name Azarga. This combination may be more effective than either medication alone.[3]
The combination ofbrinzolamide with brimonidine is marketed under the trade name Simbrinza.[4][5] This combination may be more effective than either medication alone.[4][5]
